Status: Enrolling
Investigator: Warren Ellsworth
Study Coordinator:
Phone:
This is a multicenter registry study to collect utilization, safety, and outcomes data from medical record chart review of nerve reconstruction procedures throughout the body with Avance® Nerve Graft. Addendum 1 (MATCH) establishes a comparat ... Read more >
Status: Open Not Enrolling
Investigator: Bincy Abraham
Study Coordinator: Rosa Maria Barroso Da Costa
Phone: 713.363.7536
This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely active UC who are treated as recommended in the product label. ... Read more >
Status: Enrolling
Investigator: Aldona Spiegel
Study Coordinator:
Phone:
This is a multicenter registry study to collect utilization, safety, and outcomes data from medical record chart review of nerve reconstruction procedures throughout the body with Avance® Nerve Graft. Addendum 1 (MATCH) establishes a comparat ... Read more >
Status: Enrolling
Investigator: Monisha Singh
Study Coordinator: Caroline Fitzgerald
Phone: 713.441.3250
NGM120 is an experimental drug made by NGM Biopharmaceuticals, Inc. NGM120, given as an injection, is designed to block a factor that is associated with cancer. NGM120 has shown in various animal models of cancer to reduce tumor size and improve ... Read more >
Status: Open Not Enrolling
Investigator: David Victor
Study Coordinator:
Phone:
Study to determine the effect of the investigational drug bezafibrate (BZF) alone and in combination with the investigational drug obeticholic acid (also known as OCA) in patients with Primary Biliary Cholangitis (also known as PBC). ... Read more >
Status: Enrolling
Investigator: Bincy Abraham
Study Coordinator:
Phone:
This is a study to demonstrate the effect of oral ozanimod as maintenance therapy in participants with moderately to severely active Crohn's Disease. ... Read more >
Status: Enrolling
Investigator: David Victor
Study Coordinator: Nicole Hinton
Phone: 281.755.0796
The primary objective of the Core Study is to evaluate the efficacy of volixibat versus placebo for the treatment of pruritus (as measured by the change in the Adult ItchRO tool) in participants with PSC on the basis of the following endpoint: ... Read more >
Status: Enrolling
Investigator: David Victor
Study Coordinator:
Phone:
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis stage 2 or 3. NASH - Nonalcoholic Steatohepatitis - Drug: IVA337 vs Drug: Placebo This Phase 3 study is conducted to evaluate lanifibranor in adu ... Read more >
Status: Open Not Enrolling
Investigator: David Victor
Study Coordinator: Nicole Hinton
Phone: 281.755.0796
The purpose of this randomized study is to assess safety and effectiveness of BMS-986263 in adults with compensated cirrhosis (chronic liver disease) from nonalcoholic steatohepatitis (fatty liver disease) (NASH). ... Read more >
Status: Enrolling
Investigator: David Victor
Study Coordinator:
Phone:
This is a randomized, double-blind, placebo-controlled, phase 2b clinical Trial evaluating Safety and Efficacy of DUR-928 (an experimental medication) in Patients with Alcoholic Hepatitis (AH). ... Read more >
Status: Enrolling
Investigator: Bincy Abraham
Study Coordinator:
Phone:
The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of guselkumab in participants with Crohn's disease. ... Read more >
Status: Open Not Enrolling
Investigator: Bincy Abraham
Study Coordinator: Alejandro De La Torre
Phone: 713.441.6396
The primary purpose of this study is to evaluate the efficacy and safety of a single intravenous (IV) re-induction dose of approximately 6 milligram per kilogram (mg/kg) ustekinumab in participants with secondary loss of response (LoR) to subcut ... Read more >
Status: Open Not Enrolling
Investigator: David Victor
Study Coordinator: Nicole Hinton
Phone: 281.755.0796
This study is open for men and women with a liver disease called nonalcoholic steatohepatitis (NASH) and liver fibrosis. The purpose of the study is to find out whether a medicine called BI 456906 helps patients with NASH and liver fibrosis. The ... Read more >
Status: Open Not Enrolling
Investigator: Zeenat Safdar
Study Coordinator: Royanne Holy
Phone: 713.363.7536
Study A011-09 is a Phase 2, double-blind, randomized, placebo-controlled, multicenter, parallel-group study to determine the efficacy and safety of sotatercept (ACE-011) plus standard of care (SOC) versus placebo plus SOC in adults with pulmonar ... Read more >
Status: Enrolling
Investigator: Bincy Abraham
Study Coordinator:
Phone:
This is an extension study to evaluate safety and efficacy of ozanimod in participants with moderately to severely active Crohn's Disease. ... Read more >
Status: Enrolling
Investigator: Bincy Abraham
Study Coordinator: Mayyadah Al-Sabbagh
Phone: 346.238.0307
The purpose of this study is to compare the incidence of lymphoma in adult participants with moderate-to-severe ulcerative colitis who are treated with Simponi versus those treated with thiopurines. ... Read more >
Status: Enrolling
Investigator: Bincy Abraham
Study Coordinator: Mayyadah Al-Sabbagh
Phone: 346.238.0307
This prospective, non-interventional research registry is designed to study the comparative effectiveness and comparative safety of approved treatments for IBD in a cohort of patients cared for by gastroenterologists across North America. Second ... Read more >
Status: Open Not Enrolling
Investigator: Marvin Atkins
Study Coordinator: Kim Donlon
Phone: 713.441.9394
This study is a prospective, multicenter, non-randomized single-arm study to assess the feasibility of the treatment of DeBakey Type I/II aortic dissections with the GORE® TAG® Thoracic Branch Endoprosthesis system. ... Read more >
Status: Enrolling
Investigator: Zeenat Safdar
Study Coordinator: Jennifer Lee
Phone: 713.363.7537
This registry will collect data on the strategies used to achieve a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype (ILD) and the treatment and management efforts applie ... Read more >
Status: Enrolling
Investigator: Bincy Abraham
Study Coordinator:
Phone:
This is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active Crohn's Disease. ... Read more >
Status: Enrolling
Investigator: Joseph Masdeu
Study Coordinator:
Phone:
Schizophrenic and bipolar psychoses are chronic and disabling brain disorders that affect people of all backgrounds. It is thought that in the brain of people with schizophrenic psychosis there is a decreased amount of a receptor known as the N- ... Read more >
Status: Enrolling
Investigator: Joseph Masdeu
Study Coordinator: Nilene Crisci
Phone: 281.222.1782
Some people who have what doctors currently call schizophrenia or bipolar disease may actually have a brain disease caused by auto-antibodies. Auto-antibodies are produced when the normal defense mechanism of the body goes wrong and begins to at ... Read more >
Status: Open Not Enrolling
Investigator: Bincy Abraham
Study Coordinator: Alejandro De La Torre
Phone: 713.441.6396
This open-label extension and safety monitoring study is composed of two parts: Part 1 will evaluate the long-term safety and efficacy of continued etrolizumab treatment in participants with moderately to severely active Crohn's disease who were ... Read more >
Status: Open Not Enrolling
Investigator: Sandeep Sahay
Study Coordinator: Royanne Holy
Phone: 713.363.7536
United Therapeutics Corporation (UTC) is developing a combination drug-device product which is comprised of a dry powder formulation of Treprostinil Inhalation Powder (TreT) and a small, portable, dry powder inhaler. In this Phase 1b safety and ... Read more >
Status: Enrolling
Investigator: Bincy Abraham
Study Coordinator: Mayyadah Al-Sabbagh
Phone: 346.238.0307
A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women with Inflammatory Bowel Disease study is being conducted at the University of California San Francisco and 30 other sites around the United States who are part ... Read more >
Status: Enrolling
Investigator: Zeenat Safdar
Study Coordinator: Jennifer Lee
Phone: 713.363.7537
Study ROR-PH-301 is a multicenter, randomized, double-blind, placebo-controlled study. Subjects who meet entry criteria will be randomly allocated 1:1 to receive ralinepag or placebo, in addition to their standard of care or PAH-specific backgro ... Read more >
Status: Enrolling
Investigator: Zeenat Safdar
Study Coordinator: Royanne Holy
Phone: 713.363.7536
Study ROR-PH-303 is a multicenter, open-label extension (OLE) study for subjects with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag and who qualify for entry based upon participation in the prior study. S ... Read more >
Status: Enrolling
Investigator: Rose Khavari
Study Coordinator:
Phone:
Difficulty in bladder emptying (Voiding dysfunction,VD) is a costly urinary condition that leads to urinary tract infections/stones, sepsis, bladder loss, and permanent kidney damage. VD can be present in patients with or without neurologic/brai ... Read more >
Status: Enrolling
Investigator: David Victor
Study Coordinator: Rene Andrade Ruiz
Phone: 832.768.1924
Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. Participants will either get semaglutide or a dummy medicine - which t ... Read more >
Status: Open Not Enrolling
Investigator: Neal Kleiman
Study Coordinator:
Phone:
The purpose of this study is to determine the incidence and predictors of high degree or complete atrioventricular block (AVB) (paroxysmal or persistent) in patients with new-onset persistent left bundle branch block (NOP-LBBB) following transca ... Read more >
Status: Open Not Enrolling
Investigator: Dale Hamilton
Study Coordinator: Melissa Whipple
Phone: 713.441.3247
The XLH-DMP is a global, prospective, multicenter, longitudinal, long-term outcomes program for subjects on or off any treatment designed to characterize XLH disease presentation and progression, assess long-term safety and effectiveness of buro ... Read more >
